Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Naka-ku, Hiroshima, Japan.
Leuk Lymphoma. 2011 Feb;52(2):223-9. doi: 10.3109/10428194.2010.537794. Epub 2011 Jan 24.
The Japan Association of Childhood Leukemia Study (JACLS) NHL-98 is a multicenter study designed to evaluate treatment outcomes in Japanese children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell acute lymphoblastic leukemia (B-ALL). The study was supported by a central pathology review system and used a new, standardized protocol with short, intensive treatment regimens. From April 1998 to May 2002, 69 patients with B-NHL and B-ALL up to 16 years of age were enrolled in the NHL-98 study. Treatment was stratified by risk group; patients with limited disease were in groups A and B, and those with extensive disease were in groups C and D. Patients in groups B, C, and D received consolidation phases with high-dose methotrexate (HDMTX) followed by other multi-agent chemotherapy. Patients in group A did not receive either MTX or etoposide. Only patients in group D received etoposide. The event-free survival rates were 100% in groups A and B, 75.1% in group C, and 66.2% in group D. Overall, patients with limited disease had favorable results. For patients with extensive disease, additional treatment options such as increased doses of anticancer drugs warrant further investigation.
日本儿童白血病研究协会（JACLS） NHL-98 是一项多中心研究，旨在评估日本儿童 B 细胞非霍奇金淋巴瘤（B-NHL）和成熟 B 细胞急性淋巴细胞白血病（B-ALL）的治疗结果。该研究得到了中央病理审查系统的支持，并使用了一种新的标准化方案，包括短而密集的治疗方案。1998 年 4 月至 2002 年 5 月，69 名年龄在 16 岁以下的 B-NHL 和 B-ALL 患者参加了 NHL-98 研究。治疗根据风险组分层；局限性疾病患者分为 A 组和 B 组，广泛性疾病患者分为 C 组和 D 组。B、C 和 D 组的患者接受高强度甲氨蝶呤（HDMTX）巩固阶段治疗，随后进行其他多药物化疗。A 组的患者未接受 MTX 或依托泊苷治疗。只有 D 组的患者接受依托泊苷治疗。A 组和 B 组的无事件生存率为 100%，C 组为 75.1%，D 组为 66.2%。总体而言，局限性疾病患者的结果良好。对于广泛性疾病患者，需要进一步研究增加抗癌药物剂量等额外治疗选择。
